Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of fungal infections.
As invasive fungal infection remains a common problem in the management of cancer patients, chemoprophylaxis of these opportunistic infections is desperately needed. The most frequently investigated antifungal agents have been nystatin, amphotericin B, and ketoconazole. In placebo-controlled studies, high doses of antifungal agents decreased the positive results from surveillance cultures, and there is some suggestion that such chemoprophylaxis may reduce the incidence of invasive candidiasis in neutropenic cancer patients. However, no oral chemoprophylaxis has effectively prevented aspergillosis or mucormycoses in these patients. There are still many areas of controversy, and the most adequate regimens, if any, remain to be defined.
D000284:Administration, Oral; D000287:Administration, Topical; D000666:Amphotericin B / Q000008:administration & dosage; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D006801:Humans; D007654:Ketoconazole / Q000008:administration & dosage; D008825:Miconazole / Q000008:administration & dosage; D009181:Mycoses / Q000209:etiology / Q000517:prevention & control*; D009369:Neoplasms / Q000150:complications*; D009761:Nystatin / Q000008:administration & dosage
D000935:Antifungal Agents; D009761:Nystatin; D008825:Miconazole; D000666:Amphotericin B; D007654:Ketoconazole